Lantheus (NASDAQ:LNTH) Cut to “Hold” at JonesTrading

JonesTrading downgraded shares of Lantheus (NASDAQ:LNTH) from a buy rating to a hold rating in a research report report published on Friday, MarketBeat.com reports.

A number of other equities analysts have also commented on LNTH. Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Citigroup reiterated an “outperform” rating on shares of Lantheus in a report on Tuesday, February 24th. Mizuho upped their price target on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. William Blair upgraded Lantheus from a “market perform” rating to an “outperform” rating in a research report on Thursday. Finally, Citizens Jmp lifted their target price on Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a research note on Tuesday, February 24th. Seven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Lantheus has a consensus rating of “Moderate Buy” and an average price target of $82.17.

Lantheus Trading Down 0.7%

Shares of LNTH opened at $74.91 on Friday. The business’s 50-day moving average price is $68.15 and its 200 day moving average price is $60.23. The company has a current ratio of 2.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $4.84 billion, a P/E ratio of 22.23 and a beta of -0.11. Lantheus has a 1-year low of $47.25 and a 1-year high of $111.29.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.50. The company had revenue of $406.79 million during the quarter, compared to analyst estimates of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The business’s quarterly revenue was up 4.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.59 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Analysts expect that Lantheus will post 6.01 earnings per share for the current year.

Institutional Investors Weigh In On Lantheus

Institutional investors have recently made changes to their positions in the company. Stanley Laman Group Ltd. lifted its stake in shares of Lantheus by 38.7% in the 3rd quarter. Stanley Laman Group Ltd. now owns 79,686 shares of the medical equipment provider’s stock valued at $4,087,000 after purchasing an additional 22,229 shares during the last quarter. American Assets Inc. acquired a new position in Lantheus during the third quarter worth $872,000. Campbell & CO Investment Adviser LLC bought a new position in Lantheus during the third quarter valued at about $2,184,000. Assetmark Inc. raised its holdings in Lantheus by 20.1% during the third quarter. Assetmark Inc. now owns 118,503 shares of the medical equipment provider’s stock valued at $6,078,000 after buying an additional 19,844 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Lantheus in the second quarter worth about $654,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus News Roundup

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 results: Lantheus reported $1.67 EPS vs. $1.17 expected and revenue of $406.8M vs. $367.0M expected (revenue +4% y/y), showing operational strength and margin improvement. MarketBeat Earnings Report
• Positive Sentiment: Mizuho raised its price target to $85 and set an “outperform” rating, signaling increased analyst conviction and implied upside from current levels. Benzinga
• Positive Sentiment: William Blair upgraded Lantheus from “market perform” to “outperform,” adding another positive analyst endorsement. Street Insider
• Positive Sentiment: Citizens Jmp raised its price target to $78, a modest endorsement that supports the view of upside among some sell‑side analysts. American Banking News
• Neutral Sentiment: JonesTrading reaffirmed a “hold” rating on LNTH, reflecting mixed views on near‑term catalysts. TickerReport
• Neutral Sentiment: Investor materials and transcripts are available (earnings call transcript and presentation), useful for digging into product trends, margin drivers and pipeline commentary. Yahoo Finance Transcript Seeking Alpha Deck
• Negative Sentiment: FY2026 guidance was mixed: EPS guidance of $5.00–$5.25 is roughly in line with consensus (5.16), but revenue guidance of $1.4B–$1.5B leaves room for a slight top‑line miss vs. expectations — a conservative revenue range that could weigh on near‑term sentiment. GlobeNewswire Press Release

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.